CytoDyn (OTCMKTS:CYDY – Get Free Report) announced its quarterly earnings data on Friday. The biotechnology company reported ($0.02) earnings per share for the quarter, reports.
CytoDyn Price Performance
Shares of CYDY opened at $0.27 on Friday. The firm’s 50 day moving average is $0.29 and its 200-day moving average is $0.29. CytoDyn has a 12-month low of $0.13 and a 12-month high of $0.49. The stock has a market capitalization of $341.74 million, a P/E ratio of -8.97 and a beta of 1.12.
CytoDyn Company Profile
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
Featured Articles
- Five stocks we like better than CytoDyn
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- How the Rich Retire
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
